Datapoint: Idorsia’s Quviviq Approved for Insomnia

The FDA on Monday approved Idorsia Ltd’s Quviviq for the treatment of adults with insomnia. The dual orexin receptor antagonist (DORA) will have to face off against Merck’s Belsomra and Eisai Co.’s Dayvigo, two leading DORAs in the insomnia market basket. Belsomra currently holds covered or better status for 87% of all insured lives under the pharmacy benefit, compared to Dayvigo’s 65%.

SOURCE: MMIT Analytics, as of 1/12/2022

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
January 20

Datapoint: Pfizer Scores Atopic Dermatitis Approval for Cibinqo

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
January 19

Datapoint: Centene Settles With New Hampshire in Medicaid Pharmacy Dispute

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
January 18

Datapoint: BCBSND Selected for North Dakota Medicaid Expansion

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today